Vaccines for neonatal viral infections: towards a live respiratory syncytial virus vaccine:a study in risk.
There is risk attached to the development of respiratory syncytial virus vaccines, live attenuated or otherwise, but without the acceptance of this risk by manufacturers, health providers and the public, the conclusion of successful Phase III trials may lie in the distant future.
Wyeth, Huntercombe Lane South, Taplow, Maidenhead, Berkshire SL6 0HP, UK. mcintod@wyeth.com
E D
ED
McIntosh
F J
FJ
Malinoski
V B
VB
Randolph
D006801:Humans; D007231:Infant, Newborn; D018357:Respiratory Syncytial Virus Infections / Q000517:prevention & control*; D022261:Respiratory Syncytial Virus Vaccines / Q000009:adverse effects / Q000276:immunology*; D012136:Respiratory Syncytial Viruses / Q000235:genetics / Q000502:physiology; D014614:Vaccines, Synthetic / Q000276:immunology
D022261:Respiratory Syncytial Virus Vaccines; D014614:Vaccines, Synthetic